Home / Health / BRCA Gene: Parents' New IVF Decisions
BRCA Gene: Parents' New IVF Decisions
23 Oct
Summary
- Preimplantation genetic testing (PGT-M) screens embryos for single-gene disorders like BRCA.
- IVF and PGT-M processes are lengthy, costly, and emotionally taxing for families.
- Ethical debates arise over which genetic conditions warrant PGT-M screening.
Prospective parents are increasingly using preimplantation genetic testing for monogenic disorders (PGT-M) to screen embryos for gene mutations like BRCA. This advanced technique allows for the identification of embryos carrying specific genetic markers, such as those that significantly increase the risk of developing certain cancers.
Sage Silverstein, diagnosed with breast cancer and carrying a BRCA2 mutation, utilized IVF and PGT-M to select embryos without the mutation. Her journey involved multiple cycles, egg retrieval, and the use of a gestational surrogate, underscoring the emotional and financial investment.
Similarly, K.G., a 29-year-old consultant, pursued IVF and PGT-M after discovering she carried a BRCA1 mutation. Her decision was driven by the desire to prevent her child from facing similar health risks and decisions.
Experts note that while PGT-M is highly accurate, its application raises ethical debates regarding which conditions are serious enough for screening. In the U.S., the process is less regulated than in other countries, leaving more decision-making to patients and clinicians.
The cost of IVF and PGT-M can be substantial, often ranging from $2,000 to $6,000 for the testing alone, with total IVF cycles exceeding $19,000. Insurance coverage varies, making access a significant challenge for many.
The attrition rate of eggs and embryos throughout the IVF and PGT-M process often surprises patients. This complexity leads to difficult choices, especially for those with only BRCA-affected embryos remaining, prompting discussions about future medical advancements and personal reproductive values.
